104 related articles for article (PubMed ID: 10586390)
1. Clinical pharmacokinetics of the CD19 receptor-directed tyrosine kinase inhibitor B43-Genistein in patients with B-lineage lymphoid malignancies.
Chen CL; Levine A; Rao A; O'Neill K; Messinger Y; Myers DE; Goldman F; Hurvitz C; Casper JT; Uckun FM
J Clin Pharmacol; 1999 Dec; 39(12):1248-55. PubMed ID: 10586390
[TBL] [Abstract][Full Text] [Related]
2. Treatment of therapy-refractory B-lineage acute lymphoblastic leukemia with an apoptosis-inducing CD19-directed tyrosine kinase inhibitor.
Uckun FM; Messinger Y; Chen CL; O'Neill K; Myers DE; Goldman F; Hurvitz C; Casper JT; Levine A
Clin Cancer Res; 1999 Dec; 5(12):3906-13. PubMed ID: 10632319
[TBL] [Abstract][Full Text] [Related]
3. In vivo toxicity and pharmacokinetic features of B43 (anti-CD19)-genistein immunoconjugate in nonhuman primates.
Messinger Y; Yanishevski Y; Ek O; Zeren T; Waurzyniak B; Gunther R; Chelstrom L; Chandan-Langlie M; Schneider E; Myers DE; Evans W; Uckun FM
Clin Cancer Res; 1998 Jan; 4(1):165-70. PubMed ID: 9516966
[TBL] [Abstract][Full Text] [Related]
4. In vivo toxicity and pharmacokinetic features of B43(Anti-CD19)-Genistein immunoconjugate.
Ek O; Yanishevski Y; Zeren T; Waurzyniak B; Gunther R; Chelstrom L; Chandan-Langlie M; Schneider E; Myers DE; Evans W; Uckun FM
Leuk Lymphoma; 1998 Jul; 30(3-4):389-94. PubMed ID: 9713969
[TBL] [Abstract][Full Text] [Related]
5. Membrane-associated CD19-LYN complex is an endogenous p53-independent and Bc1-2-independent regulator of apoptosis in human B-lineage lymphoma cells.
Myers DE; Jun X; Waddick KG; Forsyth C; Chelstrom LM; Gunther RL; Tumer NE; Bolen J; Uckun FM
Proc Natl Acad Sci U S A; 1995 Oct; 92(21):9575-9. PubMed ID: 7568175
[TBL] [Abstract][Full Text] [Related]
6. Large scale manufacturing of B43(anti-CD19)-genistein for clinical trials in leukemia and lymphoma.
Myers DE; Sicheneder A; Clementson D; Dvorak N; Venkatachalam T; Sev AR; Chandan-Langlie M; Uckun FM
Leuk Lymphoma; 1998 Apr; 29(3-4):329-38. PubMed ID: 9684930
[TBL] [Abstract][Full Text] [Related]
7. Biotherapy of B-cell precursor leukemia by targeting genistein to CD19-associated tyrosine kinases.
Uckun FM; Evans WE; Forsyth CJ; Waddick KG; Ahlgren LT; Chelstrom LM; Burkhardt A; Bolen J; Myers DE
Science; 1995 Feb; 267(5199):886-91. PubMed ID: 7531365
[TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetics and pharmacokinetics/pharmacodynamics of bendamustine in pediatric patients with relapsed/refractory acute leukemia.
Darwish M; Megason G; Bond M; Hellriegel E; Robertson P; Grasela T; Phillips L
Curr Med Res Opin; 2014 Nov; 30(11):2305-15. PubMed ID: 25105914
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and biodistribution of radioimmunoconjugates of anti-CD19 antibody and single-chain Fv for treatment of human B-cell malignancy.
Li Q; Hudson W; Wang D; Berven E; Uckun FM; Kersey JH
Cancer Immunol Immunother; 1998 Nov; 47(3):121-30. PubMed ID: 9829837
[TBL] [Abstract][Full Text] [Related]
10. Feasibility Study of a Novel Experimental Induction Protocol Combining B43-PAP (Anti-CD19) Immunotoxin With Standard Induction Chemotherapy in Children and Adolescents With Relapsed B-Lineage ALL: A Report From the Children's Oncology Group.
Meany HJ; Seibel NL; Krailo M; Villaluna D; Chen Z; Gaynon P; Neglia JP; Park JR; Hutchinson R; Sato JK; Wells RJ; Woods WG; Reaman G
J Immunother; 2015 Sep; 38(7):299-305. PubMed ID: 26261894
[TBL] [Abstract][Full Text] [Related]
11. Blinatumomab, a Bispecific T-cell Engager (BiTE(®)) for CD-19 Targeted Cancer Immunotherapy: Clinical Pharmacology and Its Implications.
Zhu M; Wu B; Brandl C; Johnson J; Wolf A; Chow A; Doshi S
Clin Pharmacokinet; 2016 Oct; 55(10):1271-1288. PubMed ID: 27209293
[TBL] [Abstract][Full Text] [Related]
12. Population pharmacokinetics of clofarabine and its metabolite 6-ketoclofarabine in adult and pediatric patients with cancer.
Bonate PL; Cunningham CC; Gaynon P; Jeha S; Kadota R; Lam GN; Razzouk B; Rytting M; Steinherz P; Weitman S
Cancer Chemother Pharmacol; 2011 Apr; 67(4):875-90. PubMed ID: 20582417
[TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetics of inotuzumab ozogamicin in relapsed/refractory acute lymphoblastic leukemia and non-Hodgkin lymphoma.
Garrett M; Ruiz-Garcia A; Parivar K; Hee B; Boni J
J Pharmacokinet Pharmacodyn; 2019 Jun; 46(3):211-222. PubMed ID: 30859374
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic features, immunogenicity, and toxicity of B43(anti-CD19)-pokeweed antiviral protein immunotoxin in cynomolgus monkeys.
Uckun FM; Yanishevski Y; Tumer N; Waurzyniak B; Messinger Y; Chelstrom LM; Lisowski EA; Ek O; Zeren T; Wendorf H; Langlie MC; Irvin JD; Myers DE; Fuller GB; Evans W; Gunther R
Clin Cancer Res; 1997 Mar; 3(3):325-37. PubMed ID: 9815689
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of cladribine (2-chlorodeoxyadenosine) in children with acute leukemia.
Kearns CM; Blakley RL; Santana VM; Crom WR
Cancer Res; 1994 Mar; 54(5):1235-9. PubMed ID: 7906999
[TBL] [Abstract][Full Text] [Related]
16. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
Chen C; Bujanover S; Kareht S; Rapoport AM
Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
[TBL] [Abstract][Full Text] [Related]
17. [Bone marrow immunophenotypes of 112 cases of lymphoid system malignant diseases].
Ling JY; Sun XF; Yan SL; He LR; Zhen ZJ; Xia Y
Ai Zheng; 2007 Apr; 26(4):418-22. PubMed ID: 17430665
[TBL] [Abstract][Full Text] [Related]
18. Population Pharmacokinetics and Exposure Response Assessment of CC-292, a Potent BTK Inhibitor, in Patients With Chronic Lymphocytic Leukemia.
Li Y; Ramírez-Valle F; Xue Y; Ventura JI; Gouedard O; Mei J; Takeshita K; Palmisano M; Zhou S
J Clin Pharmacol; 2017 Oct; 57(10):1279-1289. PubMed ID: 28543084
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors: correlations with clinical characteristics and safety.
Guo F; Letrent SP; Munster PN; Britten CD; Gelmon K; Tolcher AW; Sharma A
Cancer Chemother Pharmacol; 2008 Jun; 62(1):97-109. PubMed ID: 17805538
[TBL] [Abstract][Full Text] [Related]
20. PAC fixed dose: pharmacokinetics of a 1-hour paclitaxel infusion and comparison to BSA-normalized drug dosing.
Mross K; Holländer N; Frost A; Unger C; Ziroli V; Massing U
Onkologie; 2006 Oct; 29(10):444-50. PubMed ID: 17028453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
